Top

Published in:

01-04-2011 | Original Article

Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China

Authors: Bin-Tao Huang, Yu Wang, Qing-Feng Du, Jun Yang, Jessica Yu, Qing-Chun Zeng, Na Xu, Jin-Fang Zhang, Lu-Lu Xu, Xu-Jing Luo, Yong-Qiang Wei, Xiao-Li Liu

Published in: International Journal of Hematology | Issue 4/2011

Abstract

High-dose arabinoside (HiDAC) and daunorubicin (DNR)-based chemotherapy are the primary consolidation treatment options for older adults (50–60 years old) with acute myeloid leukemia in China. We analyzed the event-free survival (EFS) and hospital treatment charges of older adult patients with different cytogenetic risk profiles. In patients with a better/intermediate risk profile, the average total treatment cost of HiDAC was similar to that of DNR (P = 0.11). A 5-year follow-up of patients with better/intermediate cytogenetic risk profiles revealed that the median EFS of patients who received HiDAC was significantly longer than for patients who received the DNR-based regimen (27 vs. 20 months, P = 0.03). Average cost per year of life saved was 18,746.84 USD for HiDAC, compared to 32,733.37 USD for DNR. In contrast, for patients with a poor cytogenetic risk profile, the average total treatment cost for HiDAC was higher than for DNR (P < 0.005). In addition, the median EFS in the HiDAC protocol group was significantly lower than in the DNR group (11 vs. 20 months, P = 0.003). Meanwhile, in this risk group, the average cost per year of life saved was 103,237.70 USD compared to 32,277.93 USD, respectively, in the HiDAC and DNR regimens. We conclude that HiDAC is a more efficacious and cost-effective consolidation treatment regimen in the better/intermediate risk group, while the DNR-based regimen is more cost-effective in the poor risk group.

Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematol Am Soc Hematol Educ Program. 2004;98–117.

Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385–400.CrossRefPubMed

Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232–40.CrossRefPubMed

Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521–8.CrossRefPubMed

Fagundes EM, Rocha V, Glória AB, Clementino NC, Quintão JS, Guimarães JP, et al. De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center. Leuk Lymphoma. 2006;47:1557–64.CrossRefPubMed

Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, et al. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 2005;29:609–15.CrossRefPubMed

Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematol Am Soc Hematol Educ Program. 2009;396–405.

Bieker R, Lerchenmüller C, Wehmeyer J, Serve HL, Mesters RM, Büchner T, et al. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep. 2003;10:915–20.PubMed

Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16:872–81.CrossRefPubMed

10.

Link H, Frauer HM, Ostendorf P, Waller HD. Therapy for acute myeloid leukemia in 119 adults: a comparison of two treatment protocols. Blut. 1985;51:49–56.CrossRefPubMed

11.

Nowrousian MR, Kubaschinski G, Hossfeld DK, Schaefer UW, Schmidt CG. Results of treatment of acute myeloid leukemia in adults. Onkologie. 1983;6:184–6.PubMed

12.

Hollard D, Sotto JJ, Berthier R, Leger J, Michallet M. High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study. Cancer. 1980;45:1540–8.CrossRefPubMed

13.

Rogers BB. Advances in the management of acute myeloid leukemia in older adult patients. Oncol Nurs Forum. 2010;37:168–79.CrossRef

14.

Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110:1379–87.CrossRefPubMedPubMedCentral

15.

Paciucci PA, Cuttner J, Gottlieb A, Davis RB, Martelo O, Holland JF. Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia. Am J Hematol. 1997;56:214–8.CrossRefPubMed

16.

Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002;52:363–71.CrossRefPubMed

17.

Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin Ther. 1991;13:353–60.PubMed

18.

Yu YB, Gau JP, You JY, Chern HH, Chau WK, Tzeng CH, et al. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia. Ann Oncol. 2007;18:529–34.CrossRefPubMed

19.

Appelbaum FR, Baer MR, Carabasi MH, Coutre SE, Erba HP, Estey E, et al. NCCN practice guidelines for acute myelogenous leukemia. Oncology. 2000;14:53–61.PubMed

20.

van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86:329–37.CrossRefPubMedPubMedCentral

21.

Bassan R, Raimondi R, Lerede T, D’emilio A, Buelli M, Borleri G, et al. Outcome assessment of age group-specific (±50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. Haematologica. 1998;83:627–35.PubMed

22.

Xu W, Tang Y, Song H, Shi S, Yang S. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China. J Pediatr Hematol Oncol. 2007;29:688–93.CrossRefPubMed

23.

Redaelli A, Botteman MF, Stephens JM. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev. 2004;30:237–47.CrossRefPubMed

24.

Marie JP, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia. 1992;6:720–2.PubMed

25.

Zheng S, Song M, Wu L, Yang S, Shen J, Lu X, et al. China: public health genomics. Public Health Genomics. 2010;13:269–75.CrossRefPubMed

26.

Clavio M, Quintino S, Masoudi B, Carrara S, Cerri R, Pierri I, Canepa L, et al. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res. 2001;20:165–73.PubMed

27.

Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27:5397–403.CrossRefPubMedPubMedCentral

28.

Qian SX, Li JY, Wu HX. Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:209–13.PubMed

Title: Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China
Authors: Bin-Tao Huang
Yu Wang
Qing-Feng Du
Jun Yang
Jessica Yu
Qing-Chun Zeng
Na Xu
Jin-Fang Zhang
Lu-Lu Xu
Xu-Jing Luo
Yong-Qiang Wei
Xiao-Li Liu
Publication date: 01-04-2011
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0804-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria

High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma

All-trans-retinoic acid induced acute pancreatitis: a single or multifactorial association?

Mortality and medical morbidity beyond 2 years after allogeneic hematopoietic stem cell transplantation: experience at a single institution

Successful cord blood transplantation in a 42-day-old boy with infantile Krabbe disease

Hemostatic changes before and during electrophysiologic study and radiofrequency catheter ablation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer